Antigen-specific IgE plays an important role in the pathogenesis of allergic disorders.
Introduction
Immediate hypersensitivity disorders are associated with elevated IgE and eosinophils are important hallmarks of allergic disorders. IL-4 promotes differentiation of naive T increased IgE antibodies which cross-link the high-affinity Fcε receptors on mast cells and basophils, leading to release cells into T h 2-like cells and inhibits T h 1 activation, whereas IFN-γ suppresses IL-4-mediated T h 2 polarization both in vitro of mediators that cause allergic reactions (1) . It is well established that IgE production is regulated by a balance and in vivo (5, 6) . Fine tuning of the balance between production of T h 1-and T h 2-type cytokines is believed to be crucial between two types of cytokines, secreted by T cell subsets T h 1 and T h 2 respectively (2,3). T h 1-like lymphocytes produce for the down-regulation of IgE-mediated allergic responses and clinical sensitivity (7, 8) . IFN-γ, IL-2 and lymphotoxin, and promote immunity to intracellular pathogens as well as an Ig class switch to IgG2a.
A general strategy proposed for down-regulation of T h 2-dominant, IgE-mediated allergic disorders is to redirect T h 2-like cells secrete IL-4, IL-5, IL-10 and IL-13. IL-4 (and IL-13 in humans) is a strong promoter of switching on IgE pathogenic T h 2 responses toward less harmful T h 0/T h 1 responses by up-regulating the production of T h 1-type cytoproduction in B lymphocytes, while IL-5 plays an important role in activation and recruitment of eosinophils (4) (5) (6) . Both kines (9) . Unmethylated CpG motifs common in bacterial, but not mammalian, DNA have been shown to induce strong by Oligos Etc. (Wilsonville, OR) in a good manufacturing T h 1-biased immunity in vivo (10) (11) (12) (13) (14) and in vitro (15, 16) . Their practice facility and had undetectable lipopolysaccharide use in infectious diseases, allergy and cancer in animal contaminants. models may provide a broadly effective means of directing Aed a 2 is a 37 kDa salivary protein of mosquito Aedes or redirecting immune responses (9, 17, 18) . Synthetic CpG aegypti and is also found in many other mosquito species oligodeoxynucleotides (ODN) have recently been shown to with worldwide distribution (22, 23) . This protein causes be potential immunoregulators in prevention of airway positive skin tests and binds to serum IgE in mosquito-allergic inflammation and hyper-responsiveness in murine models subjects (22,23). The cDNA coding for Aed a 2 was cloned (10) (11) (12) 14) . These studies suggest the therapeutic potential (24) and the recombinant protein was expressed by a baculoof bacterial DNA in prevention and perhaps in treatment of virus/insect cell system and purified using DEAE-Sephacel IgE-mediated allergic disorders.
as described elsewhere (25) . Purified rAed a 2 induces a CpG ODN can be produced in large quantities under typical T h 2-type response following repeated intradermal (i.d.) controlled conditions and therefore have important potential injections in mice (25) . as an immunotherapeutic agent. Many aspects remain to be clarified before their widespread application to immunoSensitization regulation in humans, however. Firstly, the animal models No adjuvants were used in these studies. ODN without used extensively in the allergy and CpG ODN studies are immunostimulatory CpG motifs were not included in this sensitized either by addition of adjuvant (11, 12, 14, 19) or by study because previous studies clearly showed a CpG motifinfrequent allergen injections via unnatural routes such as the dependent activity of synthetic ODN in immune regulation peritoneum (10) . Because adjuvants themselves induce non- (10, 12, 14, 19, 21) . The time-lines in the prevention study and in specific T cell and inflammatory responses, and affect multiple the ongoing IgE study are shown in Figs 1 and 3 respectively. cellular functions (20) , these findings need to be translated Each immunization is represented by an arrow, CpG into models which more closely approximate the triggering of administration is shown by a CpG-labeled arrow and antibody IgE responses under natural conditions in humans, i.e. when measurements by symbols. the allergenic stimulus is not accompanied by an adjuvant, In the prevention study ( Fig. 1) , four BALB/c mice in each the portal entry of the allergen is natural and the exposure to group were pretreated (i.d.) with a mixture of 10 µg of rAed the allergen is frequent. Secondly, since T h 1 immunity is a 2 and 10, 30 or 90 µg of CpG ODN in saline at day 0. On enhanced following plasmid DNA or CpG ODN vaccination, the same day, two other groups of mice were injected i.d. the potential for harmful delayed-type hypersensitivity with 10 µg of rAed a 2 as positive controls and saline as responses induced by CpG ODN vaccination needs to be negative controls respectively. Seven days later, all mice were determined. Finally, the production of antigen-specific IgE sensitized i.d. with 10 µg of rAed a 2 in saline twice a week plays an important role in the mediation of allergic reactions, for 5 weeks, except for the negative control group which was but the alterations of antigen-specific IgE production following treated with saline only. After confirming the induction of CpG ODN administration are controversial and are not well serum rAed a 2-specific IgE in the positive control group at investigated. week 5, all mice were sacrificed and spleen lymphocyte In this study, utilizing a mouse model sensitized with a suspensions were prepared for antigen-induced cytokine recombinant mosquito saliva allergen (rAed a 2) via a natural assays. Blood samples were collected by tail bleeding at route, without use of adjuvants, we examined the therapeutic week 0, 2.5 and 5, and sera were stored at -70°C for effects of CpG ODN on both developing and ongoing IgE measurement of antigen-specific IgE, IgG1 and IgG2a antiresponses and characterized type 1/type 2 cytokine expresbodies, and IL-12 (p40). To confirm the results, a similar sion patterns. The occurrence of delayed-type hypersensitivity experiment using ovalbumin as antigen was performed. reactions, a potentially limiting side effect of CpG ODN To determine the effect of CpG ODN vaccination on vaccination, was also examined.
established IgE responses, CpG ODN vaccination was given twice after sensitization with rAed a 2 ( Fig. 3) . CpG ODN at Methods 30 µg was chosen as an optimal dose in these experiments. This dose is also compatible with the dose used in a previous Mice study (10) . In addition, two mouse strains, the T h 2-biased Female BALB/c and C57BL/6 mice (8-10 weeks old) were BALB/c and T h 1-biased C57BL/6, were utilized to evaluate obtained from the Central Animal Care Services, University the effect of genetic factors on the outcome of CpG ODN of Manitoba. All animals were kept under identical conditions vaccination. BALB/c and C57BL/6 mice (four in each group) in one room at the Service facility. The experiments were were first sensitized i.d. with 10 µg of rAed a 2 twice weekly approved by the University of Manitoba and the Animal for 8 weeks. Serum rAed a 2-specific IgE was significantly Care and Use Committee, and the investigators adhered to increased in the positive control group at week 4. The mice Canadian Council on Animal Care (CCAC) guidelines for were then challenged i.d. with 2 µg of rAed a 2 at weeks 9.5 humane treatment of animals. and 11.5. At weeks 4 and 8, one group of rAed a 2-sensitized mice was injected i.d. with a mixture of 30 µg of CpG ODN CpG ODN and rAed a 2 and 10 µg of rAed a 2. The other group of rAed a 2-sensitized mice was treated with 10 µg of rAed a 2 alone. Control mice The CpG ODN, consisting of 20 bases containing two CpG motifs (TCCATGACGTTCCTGACGTT) (10, 21) , were produced were injected with saline. Sera were collected biweekly.
Intradermal tests
into the shaved back of each mouse; 10 µl of saline was injected as a negative control 2 cm away from the antigen Intradermal tests were performed as previously reported (25) .
injection site. The immediate reaction was read 20 min Briefly, 1 µg of rAed a 2 in 10 µl of saline was injected i.d.
after the injection by measuring the largest and orthogonal diameters of the wheal. The delayed reaction was read 24 and 48 h later by measuring the induration. The visibility of the edge of the wheal or induration was enhanced by wrinkling the skin surrounding the injection site. After subtraction of the saline-induced wheal or induration, the results were expressed using the average diameter of the wheal or the induration. A diameter ജ5 mm was considered to be positive.
Serum antigen-specific IgE, IgG1 and IgG2a
Serum samples were collected at weeks 0, 1, 2.5 and 5 in the prevention study, and every 2 weeks in the treatment study. rAed a 2-specific IgE was measured using a reversetype, anti-IgE capture ELISA according to techniques previously developed in our laboratory (25) . Briefly, 96-well microplates coated with monoclonal rat anti-mouse IgE (PharMingen, San Diego, CA) were incubated with test samples (1:10), followed by incubations with biotinylated rAed a 2 (0.5 µg/ml) prepared in our laboratory according to an established procedure (26) and then streptavidin-alkaline phosphatase conjugate (1:1,000) (PharMingen). rAed a 2-specific IgG1 and IgG2a were measured using an antigen capture ELISA as described previously (27,28). Briefly, the plates were coated with 0.25 and 1 µg/ml of rAed a 2 for testing IgG1 and IgG2a respectively, and then incubated with serum samples or a standard reference serum (1:1000 for IgG1 and 1:40 for IgG2a) or PBS followed by incubation with alkaline phosphatase-conjugated monoclonal rat antibodies against mouse IgG1 (1:10,000) or IgG2a (1:1000). The standard reference serum was obtained from a pool of rAed a 2-immunized mice with high titer antibody levels.
Test samples were assayed in duplicate. The mean value of each samples was expressed by the optical absorbency at 405 nm (OD 405 ) after deduction of the PBS control, and then normalized using the standard reference serum (25) .
Antigen-induced cytokine production
Mouse spleen cell suspensions were prepared as described previously (28) and cultured in triplicate to a final concentration of 2ϫ10 6 cells/ml (total 200 µl/well) in complete RPMI 1640 medium supplemented with 10% FCS. rAed a 2 was added to cultures at 50 µg/ml. Cells cultured with the medium alone served as an unstimulated control. Culture supernatants were harvested at day 3 and day 4, and stored at -70°C until (1.5-fold, P Ͻ 0.01) and IL-12 (1.8-fold, P Ͼ 0.05), confirming a T h 2-like dominant response in this model. Consistent with cytokine analysis.
The levels of IL-4, IL-5 and IFN-γ in the culture supernatant their suppressed IgE production, CpG ODN-vaccinated mice showed significantly decreased production of IL-4 (P Ͻ 0.01) and IL-12 (p40) in serum were determined by sandwich ELISA (28) with reagents purchased from PharMingen. Briefly, 96-and IL-5 (P Ͻ 0.001), and increased secretion of IFN-γ and IL-12, indicating that a switch from a T h 2-to a T h 1-type well plates were coated with purified monoclonal rat antimouse IL-4 or IL-5, IL-12 (p40) and IFN-γ (1-2 µg/ml), and immune response occurs following CpG ODN vaccination. Analysis of the kinetics of serum IL-12 production revealed then incubated with test culture supernatants (undiluted and 1:2) or a recombinant standard (IL-4, 0.25-500 pg/ml; IL-5, that 1 week after vaccination, an intense but transient increase in IL-12 production occurred in CpG ODN-2.5-2500 pg/ml; IL-12, 4-4000 pg/ml; IFN-γ, 1-1000 pg/ml). This was followed by incubations with biotinylated monovaccinated mice (P Ͻ 0.01) (Fig. 1D) . The high IL-12 levels persisted for 1-2 weeks and then declined. This early producclonal rat anti-mouse IL-4 or IL-5, IL-12 (p40) and IFN-γ (0.5-1 µg/ml), and finally streptavidin-alkaline phosphatase tion of IL-12 may be critical for the later establishment of T h 1 dominance in this model. (1:1,000) . The sensitivity of the assay was 2 pg/ml for IL-4, 10 pg/ml for IL-5, 8 pg/ml for IL-12 and 16 pg/ml for IFN-γ
The effect of CpG ODN on down-regulation of ongoing IgE respectively.
responses Statistical analysis
Frequent immunizations with rAed a 2 in BALB/c mice resulted in a steady increase in serum rAed a 2-specific IgE and IgG1 The levels of specific antibodies and cytokines and the levels, as shown in Fig. 3(A1) . Surprisingly, compared with diameters of the skin reactions were expressed as mean Ϯ the positive controls, 3C1 ) and a transitory increase in serum IL-12, which reached a peak 2 weeks following CpG The effect of CpG ODN vaccination on prevention of IgE ODN administration and returned to baseline by 4 weeks responses (P Ͻ 0.01 at weeks 6 and 10 respectively) (Fig. 3D1) .
To confirm this, two other experiments were performed The effect of CpG ODN vaccination on prevention of subsequent sensitization to rAed a 2 is shown in Fig. 1 . using ovalbumin in which CpG ODN was administered at week 1 or weeks 2, 3 or 4 respectively after sensitization After sensitization at week 5, positive control mice developed significantly higher levels of specific IgE and commenced. Similar results were found: ongoing IgE responses were not suppressed although serum IgG2a and IgG1 but very low levels of IgG2a (Fig. 1A-C) , consistent with our previous observations (25) . CpG ODN vaccination IL-12 were up-regulated (29).
As shown in Fig. 3 (right panel), in C57BL/6 mice, rAed a 2 suppressed specific IgE levels by 90% compared with positive control mice (P Ͻ 0.05) (Fig. 1A) . Unlike IgE, rAed a 2-specific sensitization induced an increase in IgE and IgG1, and a small increase in IgG2a. Compared with BALB/c mice, however, the IgG1 production was not inhibited by CpG ODN treatment (Fig. 1B) . As expected, a dose-dependent increase in rAed overall levels of IgE, IgG1 and IgG2a were lower than those in BALB/c mice. Similar to the results in BALB/c mice, CpG a 2-specific IgG2a was observed in CpG ODN-vaccinated mice (P Ͻ 0.01) (Fig. 1C) . Moreover, all CpG ODN-treated ODN vaccination failed to down-regulate the ongoing IgE and IgG1 responses at all despite the fact that serum IL-12 levels mice appeared healthy, consistent with previous reports (21) . The same results were obtained using ovalbumin; one dose were significantly up-regulated and IgG2a levels were slightly increased. of CpG ODN administration 1 week before sensitization induced a substantial suppression of IgE responses up to 7 Immediate and delayed skin reactions were assessed at weeks 4, 8 and 12. There was no difference in the size of the weeks (29).
The effect of CpG ODN on skin reactions to rAed a 2 is immediate wheal reactions between the CpG ODN-vaccinated and positive control groups in both strains ( 2). There was no delayed skin reaction observed in any other group during the study. group. As IgG1 also plays a role in mast cell-mediated inflammation in mice, but not in humans (30), the unchanged IgG1 levels in CpG ODN-vaccinated mice may account for Discussion the incomplete suppression of the immediate skin reactions in this group.
In this study, pretreatment with a single dose of CpG ODN mixed with rAed a 2 consistently inhibited subsequent producThe effect of CpG ODN on antigen-induced cytokine responses 5 weeks after CpG ODN vaccination is shown in tion of antigen-specific IgE and induced antigen-specific IgG2a for at least 5 weeks (Fig. 1) . The inhibition of IgE Fig. 2 . Compared to unimmunized mice, positive control mice produced significantly higher levels of IL-4 (Ͼ9-fold, P Ͻ responses was associated with increased production of IFN-γ and IL-12, and decreased production of IL-4 and IL-5 by 0.01) and IL-5 (Ͼ40-fold, P Ͻ 0.0001), and slightly more IFN-γ Four mice in each group were pretreated i.d. with rAed a 2 ϩ CpG ODN at week 0. One week later, the mice were sensitized i.d. with rAed a 2 from week 1 to 5 as described in Methods. Skin testing was performed at week 5. The immediate wheal sizes in rAed a 2-sensitized mice with or without CpG ODN treatment were significantly larger than those in saline control mice (P Ͻ 0.001). CpG ODN-vaccinated mice generally produced smaller wheals compared with untreated group (P values are shown in the parentheses). Fig. 2 . The effect of CpG ODN vaccination on cytokine induction. Four mice in each group were treated as described in Fig 1. Splenocytes from mice treated with 90 µg of CpG ODN plus rAed a 2, or rAed a 2 alone, or saline were stimulated in vitro with 50 µg/ml of rAed a 2 for 3 days. The levels of IL-4, IL-5, IL-12 (p40) and IFN-γ (mean Ϯ SEM) were measured by ELISA. Cytokine production in the absence of rAed a 2 in culture was undetectable. The cytokine levels from day 4 culture exhibited similar patterns (data not shown).
rAed a 2-re-stimulated spleen cells. Our data support a role production has already been demonstrated in vitro (32) and in vivo (33, 34) . Similar findings, a T h 0-type response, i.e. an of CpG ODN in switching on T h 1 immunity to a protein antigen through up-regulation of T h 1-type cytokines and downincrease in both IgG1 and IgG2a, have been observed following intranasal co-administration of hepatitis B surface regulation of T h 2-type cytokines, indicating the ability of CpG ODN to hinder allergic sensitization (10, 11, 13) in mice antigen with CpG ODN (35) . Strikingly, treatment with CpG ODN in rAed a 2-sensitized sensitized without adjuvant. Although both IFN-γ and IL-12 are involved in the protection against the development of T h 2-mice failed to inhibit established IgE responses in both BALB/c and C57BL/6 mice (Fig. 3) . Presumably, when CpG mediated allergic responses, other mechanisms may also be important in inducing this protection (31) .
ODN are administered 4 weeks after antigen sensitization, IgE-secreting plasma cells would already be present in the The successful inhibition of the production of IgE, but not IgG1, by CpG ODN in primary immune responses to rAed a bone marrow and would likely be refractory to further T h 1 stimuli. This is supported by the evidence that IgE-committed 2 indicates that the production of IgG1 and IgE antibodies to rAed a 2 is differentially regulated. This is not surprising B lymphocytes may be resistant to exogenous stimuli such as IL-4 and anti-CD40 antibodies (36) . Recently, it has been because the dissociation in regulation of IgE and IgG1 There was no difference in the sizes of the immediate wheal reactions between the CpG ODN-vaccinated and positive control groups in both strains, although all of them developed significantly larger immediate wheal sizes than those in saline controls (P Ͻ 0.001). In the CpG ODN vaccinated group, however, a delayed skin reaction was observed in three out of four mice (P Ͻ 0.02).
found that incubation of CpG ODN with human peripheral for this discrepancy may be the alum adjuvant used and/or the route of administration delivering CpG ODN through blood mononuclear cells from allergic donors results in suppression of total IgE production, whereas the antigen-specific mucus membrane or skin, and the frequency of sensitization, which may influence the IgE production differently in the IgE secretion remains unaltered (16) . This is accompanied by elevated expression of IL-12 and IL-18 mRNA (16). Our models. Another explanation may be that the effect of CpG ODN is antigen dependent. This is not likely because we analysis of serum IL-12 and total IgE levels revealed an increased IL-12 ( Fig. 3D ) but an unchanged total IgE or rAed repeated the experiment with ovalbumin and obtained similar results that administration of CpG ODN even 1 week after a 2-specific IgE production following CpG ODN administration ( Fig. 3A; total IgE responses similar to rAed a 2-specific IgE, sensitization started did not down-regulate IgE responses (29). data not shown). As shown in Fig. 3(D) , even though serum Consistent with the unaltered specific IgE levels in CpG IL-12 levels are maintained at a high level after week 4 ODN-vaccinated, pre-sensitized mice, immediate skin reacby repeated administration of CpG ODN, the ongoing IgE tions were also unchanged. Surprisingly, CpG ODN responses are not affected. Our data obtained in mice vaccination induced transient delayed skin reactions at frequently sensitized without adjuvant suggests that week 8 in BALB/c mice after the second injection of CpG increased T h 1 immunity induced by CpG ODN does not ODN (Table 2) . To our knowledge, this is the first time a inhibit established IgE responses. This is supported by potential visible side effect of CpG ODN on the treatment of recent studies in which passively transferred T h 1 cells did not IgE responses to an allergen has been reported. Delayed inhibit T h 2 responses efficiently in vivo (37) and CpG ODN skin reactions were not found in mice receiving one CpG was unable to redirect a neonatally established T h 2 response ODN injection before sensitization, suggesting that delayed to tetanus toxoid antigen (19). Interestingly, we have recently skin reactions may be correlated to the number of injections found that although CpG ODN has little effect on downof CpG ODN. Genetic background may also influence the regulation of ongoing IgE production, administration of this severity of this side effect because C57BL/6 mice, a T h 1-vaccine intranasally is highly effective in suppression of airway biased strain (40), produced rather lower levels of IgE, IgG1 eosinophilia in mice with elevated serum IgE (29).
and IgG2a, and did not develop delayed hypersensitivity skin Other studies in murine asthma models have shown that reactions following CpG ODN vaccination. CpG ODN efficiently suppresses airway eosinophilia and IgE-mediated disorders are a rapidly increasing problem, hyper-responsiveness. In these studies, the mice were especially in developed countries (41, 42) . Our study persensitized infrequently (2-4 times) with allergen either through formed in a mouse model in which mice were frequently an unnatural route such as the peritoneum (10) or using alum sensitized without adjuvant demonstrated that CpG ODN as an adjuvant (11, 12, 14) . It has long been known that vaccination may provide an effective and economic approach adjuvants can influence the nature and cellular functions of for preventing IgE production, and reducing the risk of the immune response (20) . Systemic sensitization with allerdeveloping allergic disorders. The therapeutic potential of gen plus adjuvant Al(OH) 3 induces the highest levels of IgE CpG ODN vaccination for established allergic disease clearly and eosinophil infiltration compared with protocols without needs to be investigated further using animal models that adjuvants (38, 39) . Thus, the non-specific effect of the adjuvant relate more closely to humans. may increase the complexity of the responses to CpG ODN. In the study by Sur et 
